THERAPY DOSSIER · th-1a44318295e8

RS504393

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23934512 ↗2013Reported benefit

Chemokine CCL2 induces apoptosis in cortex following traumatic brain injury.

RatTBIWeight-drop / impact-accelerationSprague-DawleyMaleAssessed 3 days after injury

Model: Local cortical traumatic brain injury induced by Feeney weight-drop

CCL2 and CCR2 mRNA rose for at least 10 days after injury, peaking at day 3, and the CCR2 antagonist RS504393 reduced TUNEL staining and improved Morris water maze performance at 3 days.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…